A newly published paper in The Lancet Oncology has provided early data from the LATITUDE trial on patient-reported outcomes (PROs) and health-related quality of life (HRQoL) for men with newly diagnosed, high-risk, metastatic, castration-naive prostate cancer. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: adverse, effect, latitude, life, pain, quality, risk, trial | Leave a comment »
It has long between understood that there is an association between a man’s serum levels of vitamin D and his risk for prostate cancer in general and clinically significant prostate cancer in particular. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: adverse, pathology, radical prostatectomy, risk, vitamin D | 6 Comments »
A recent report in European Urology found that, in spite of three randomized clinical trials (RCTs) that proved the efficacy of immediate or adjuvant radiation following surgery with adverse pathology results compared to a wait-and-see approach, a lower percentage of such patients are actually getting adjuvant treatment. Why should this be? … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: adjuvant, adverse, pathology, post-surgery, radiation | 2 Comments »
Yesterday we commented (by request) on a paper by Klotz et al. suggesting that initial treatment with the LHRH antagonist degarelix might have benefits compared to initial treatment with an LHRH agonist such as leuprolide or goserelin acetate. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: adverse, Degarelix, event, LHRH agonist, outcome, trreatment | 1 Comment »
A newly published study in BJU International suggests (unsurprisingly) that androgen deprivation therapy (ADT) is associated with an increased risk of death among men with such cardiovascular conditions as congestive heart failure or prior heart attacks. … READ MORE …
Filed under: Living with Prostate Cancer, Management | Tagged: ADT, adverse, androgen, cardiac, deprivation, effect, heart, risk | 2 Comments »
The “New” Prostate Cancer InfoLink is utterly unsurprised to learn about a forthcoming paper demonstrating that many men starting treatment with androgen deprivation therapy (ADT) — and their partners — are significantly under-informed about the risk for side effects and adverse effects associated with such therapy. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, adverse, androgen, deprivation, effects, LHRH, side | 10 Comments »
The U.S. Food & Drug Adminstration (FDA), yesterday, issued a statement about modifications to the labeling (the product prescribing information) for the two branded formulations of finasteride: Propecia® (finasteride 1 mg) and Proscar® (finasteride 5 mg). These modifications to the product labeling may be relevant to some men with or at risk for prostate cancer. … READ MORE …
Filed under: Uncategorized | Tagged: adverse, effect, finasteride, side | Leave a comment »
